An isoprenic acid derivative and its uses
By upregulating LDLR and inhibiting PCSK9 using isoprenoic acid derivatives, the side effects of statins and the high cost of PCSK9 inhibitors have been addressed, achieving a significant reduction in LDL-C levels and providing a new treatment option for cardiovascular diseases.
Patent Information
- Application Number
- CN202510625167.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-15
- Publication Date
- 2026-11-17
AI Technical Summary
Existing statins have limited side effects and efficacy in lowering low-density lipoprotein cholesterol (LDL-C) levels, especially in patients with hereditary hypercholesterolemia, and the high cost and injection-only nature of PCSK9 inhibitors limit their widespread use.
A new isoprenic acid derivative was developed to regulate LDL-C levels through a dual mechanism, namely by upregulating the low-density lipoprotein receptor (LDLR) and inhibiting the proprotein convertase subtilisin 9 (PCSK9), thereby reducing LDL-C in the blood.
It significantly reduces LDL-C levels, provides diverse treatment options, and is suitable for patients who are intolerant to or do not respond well to statins, especially those with cholesterol metabolism disorders such as hypercholesterolemia and atherosclerosis.
Smart Images

Figure CN123106413A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the pharmaceutical field, specifically to isoprenic acid derivatives and their use in treating cardiovascular diseases, metabolic diseases, and other diseases related to lipid metabolism disorders, including those associated with low-density lipoprotein receptor (LDLR) and proprotein convertase subtilisin 9 (PCSK9). Background Technology
[0002] Cardiovascular disease (CVD) is one of the leading causes of death and disability worldwide, encompassing various types including coronary heart disease, hypertension, myocardial infarction, and stroke. The occurrence of CVD is closely related to abnormal blood lipid levels, particularly elevated low-density lipoprotein cholesterol (LDL-C), which has been identified as a significant risk factor for CVD (Eur. Heart J. 2017, 38, 2459-2472). Therefore, lowering LDL-C levels is a crucial strategy for the prevention and treatment of CVD. Currently, statins are primarily used clinically to control LDL-C levels and reduce the risk of cardiovascular events.
[0003] Statins are a class of 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) inhibitors that primarily lower LDL-C levels in the blood by inhibiting cholesterol synthesis, thereby reducing the risk of atherosclerosis. However, statin use is accompanied by certain side effects, including muscle pain, fatigue, and even serious adverse reactions such as rhabdomyolysis (Am. Heart J. 2014, 168(1), 6-15). These side effects make it difficult for some patients to tolerate statin treatment long-term. In addition, some patients respond poorly to statins, especially in patients with hereditary hypercholesterolemia, where the efficacy of statins is limited and it is difficult to achieve the ideal control target for LDL-C levels. Therefore, in order to meet the treatment needs of cardiovascular diseases, the development of novel lipid-lowering drugs with unique mechanisms of action and fewer side effects has become an urgent clinical problem to be solved.
[0004] In the regulation of lipid metabolism, the low-density lipoprotein receptor (LDL receptor) plays a crucial role in regulating LDL-C levels in the blood. LDLR can bind to LDL particles in the blood and transport them to hepatocytes for metabolism, thereby effectively reducing LDL-C levels in the blood (Curr. Med. Chem. 2020, 27(2), 317-333). The expression level of LDLR directly affects the efficiency of cholesterol metabolism; therefore, activating or upregulating LDLR has become an effective lipid-lowering strategy. In recent years, studies have found that the proprotein convertase subtilisin / KexinType 9 (PCSK9) also plays an important role in regulating LDLR levels. PCSK9 is a secreted protein that promotes the degradation of LDLR by binding to it, leading to a decrease in LDLR levels on the surface of hepatocytes, thereby reducing LDL-C clearance. Therefore, inhibiting PCSK9 expression or preventing PCSK9 from binding to LDLR can effectively enhance the activity of LDLR on the surface of hepatocytes, thereby enhancing the metabolic clearance efficiency of LDL-C (Atherosclerosis. 2015, 238(2), 264-270).
[0005] Based on the above mechanisms, some lipid-lowering drugs have already targeted PCSK9. For example, PCSK9 inhibitors such as alirocumab, evolocumab, tafolecimab, and inclisiran are already used clinically. These drugs have shown significant lipid-lowering effects by targeting the PCSK9 protein or inhibiting the expression of the PCSK9 gene (Nat. Rev. Cardiol. 2014, 11(10), 563-575). However, the high cost of PCSK9 inhibitors and the need for injection administration limit their widespread application and patient compliance. In addition, the effects of simply inhibiting PCSK9 or simply upregulating LDLR are still limited. Therefore, drugs with a dual mechanism of action that upregulates LDLR while simultaneously inhibiting PCSK9 have higher lipid-lowering potential. These dual-mechanism drugs are expected to play a significant role in controlling LDL-C levels and provide a new solution for the treatment of cardiovascular diseases.
[0006] Against this backdrop, developing novel compounds that can upregulate LDLR while simultaneously inhibiting PCSK9 has significant clinical implications. These compounds can not only enhance LDL-C clearance efficiency and lower blood lipid levels, but also avoid the limitations of current single-target drugs, filling gaps in existing lipid-lowering treatment regimens and providing patients with more diverse treatment options. Summary of the Invention
[0007] One object of the present invention is to provide an isoprenic acid derivative or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, a solvate thereof, or a prodrug thereof, wherein the isoprenic acid derivative has a significant effect in upregulating low-density lipoprotein receptor (LDLR) and inhibiting proprotein convertase subtilisin 9 (PCSK9), thereby effectively reducing the level of low-density lipoprotein cholesterol (LDL-C) in the blood.
[0008] The structure of the isoprenic acid derivative is shown in the following general structural formula (I):
[0009]
[0010] R 1 It can be methyl, phenyl, aryl, heterocyclic, hydrocarbon, hydrocarbon with functional groups, or deuterated hydrocarbon;
[0011] R 2 It can be phenyl, aryl, heterocyclic, hydrocarbon, or a hydrocarbon group with a functional group;
[0012] n is 1, 2, 3 or 4;
[0013] Wherein, the aryl group is a phenyl group with substituents at the ortho, meta, and para positions, and the substituents include alkyl, alkenyl, phenyl, halogen, difluoromethyl, trifluoromethyl, alkoxy, alkoxycarbonyl, acyl, acyloxy, amide, sulfonyl, sulfonyloxy, hydroxyl, nitro, carboxyl, cyano, and amino; the heterocyclic group refers to a 3-10 membered heterocycle with carbon, nitrogen, oxygen, or sulfur atoms as the cyclic atom, and is an aliphatic ring, aromatic ring, or a ring composed of two or more simple rings; among the hydrocarbon groups with functional groups, the functional groups include acyl, hydroxyl, halogen, alkoxy, alkoxycarbonyl, formyl, acyloxy, amide, sulfonyl, sulfonyloxy, nitro, carboxyl, and cyano;
[0014] Preferably,
[0015] R 1 It can be alkyl, deuterated alkyl, haloalkyl, cycloalkyl, epoxyalkyl, phenyl, or aromatic heterocyclic.
[0016] R 2 It can be alkyl, cycloalkyl, epoxyalkyl, aromatic heterocyclic, phenyl, methylphenyl, trimethylphenyl, methoxyphenyl, or naphthyl;
[0017] n is preferably 2, and n can be 1 or 3.
[0018] The isoprenic acid derivatives described in this invention include all possible stereoisomers, including but not limited to cis-trans isomers and enantiomers.
[0019] The isoprenic acid derivatives represented by structural formula (I) described in this invention can be reacted with inorganic or organic bases to prepare "pharmaceutically acceptable salts," including but not limited to chlorides, bromides, phosphates, citrates, and succinates. These forms can increase the stability of the compound and optimize its bioavailability, thereby improving its therapeutic efficacy.
[0020] The solvents used to form solvates in this invention include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. Furthermore, these compounds can also form cocrystals with suitable cocrystal precursors to improve the solubility and stability of the drug.
[0021] The present invention also provides a pharmaceutical / pharmaceutical composition comprising a therapeutically effective amount of the isoprenic acid derivative of the present invention or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, or a solvate thereof or a prodrug thereof, combined with a pharmaceutically acceptable carrier and excipients.
[0022] The drug / drug composition is used to treat, prevent and / or alleviate diseases or conditions caused by lipid metabolism disorders, cholesterol level imbalances, LDLR level abnormalities and / or PCSK9 level abnormalities.
[0023] Furthermore, the drug / drug composition can be used alone and / or in combination with other drugs.
[0024] Preferably, the pharmaceutically acceptable carrier refers to a carrier that, when properly administered to animals or humans, does not produce adverse, allergic, or other adverse reactions. Pharmaceutically acceptable carriers include, but are not limited to: sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium methylcellulose, ethylcellulose, and methylcellulose; tragacanth gum powder; malt; gelatin; talc; solid lubricants such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and cocoa butter; polyols such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers such as Tween-20 / 80; wetting agents such as sodium lauryl sulfate; colorants; flavoring agents; tableting agents; stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic salt solutions; and phosphate buffers, etc. These substances are used as needed to help stabilize the formulation or to improve its activity or bioavailability or to produce an acceptable taste or smell when taken orally.
[0025] Specifically, the drug / drug composition may also contain physiologically compatible excipients, including buffers, diluents, excipients, fillers, binders, humectants, disintegrants, absorption enhancers, surfactants, adsorbents, lubricants, etc.
[0026] Specifically, the drug / drug composition can be formulated into injections, sterile powders for injection, tablets, pills, capsules, lozenges, liniments, powders, granules, syrups, solutions, tinctures, aerosols, powder inhalers, or suppositories, etc. All of the above dosage forms of the drug / drug composition can be prepared according to conventional methods in the pharmaceutical field.
[0027] Specifically, the drug / drug composition can be introduced into the body, such as into muscles, intradermal tissues, subcutaneous tissues, veins, or mucous membranes, via injection, spray, nasal drops, eye drops, penetration, absorption, or physical or chemical mediated methods; or it can be introduced into the body after being mixed with or encapsulated by other substances. Preferably, it is administered by injection. The drug / drug composition can also be used in combination with other treatment methods, including surgery, radiotherapy, chemotherapy, and targeted therapy.
[0028] This invention also provides the use of the aforementioned isoprenic acid derivatives or pharmaceutically acceptable salts or stereoisomers thereof, or solvates thereof, or prodrugs thereof, or pharmaceutical / pharmaceutical compositions, in the preparation of medicaments for the treatment and / or prevention and relief of diseases associated with lipid metabolism disorders. By effectively modulating the activity of LDLR and PCSK9, the compounds of this invention can be used to improve hypercholesterolemia caused by elevated LDL-C and provide patients with more diverse treatment options.
[0029] The present invention also provides the use of the said isoprenic acid derivative or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, or a solvate thereof, or a prodrug thereof, or a drug / drug composition thereof, in the preparation of a drug for regulating and / or increasing low-density lipoprotein receptor (LDLR) levels.
[0030] The present invention also provides the use of the aforementioned isoprenic acid derivative or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, or a solvate thereof, or a prodrug thereof, or a drug / drug composition thereof, in the preparation of a medicament for regulating and / or inhibiting the level of the proprotein convertase subtilisin 9 (PCSK9).
[0031] The present invention also provides the use of the aforementioned isoprenic acid derivative or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a drug / drug composition thereof in the preparation of a medicament for treating a disease or condition associated with abnormal LDLR levels.
[0032] The present invention also provides the use of the aforementioned isoprenic acid derivative or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a drug / drug composition thereof in the preparation of a medicament for treating a disease or condition associated with abnormal PCSK9 levels.
[0033] The diseases or conditions mentioned include those related to lipid metabolism abnormalities, abnormal cholesterol levels and dyslipidemia, cancer and / or other conditions.
[0034] Among them, the diseases related to lipid metabolism abnormalities include cardiovascular diseases (such as coronary artery disease, atherosclerosis, coronary heart disease, myocardial infarction, and stroke), metabolic diseases (such as diabetes, obesity, metabolic syndrome, fatty liver, and insulin resistance), endocrine disorders (such as hyperlipidemia and hypercholesterolemia), cancer, and / or other conditions.
[0035] The abnormal cholesterol levels include fatty liver.
[0036] The present invention also provides a method for treating and / or preventing or alleviating diseases associated with lipid metabolism disorders, the method comprising administering to a subject individual an isoprenic acid derivative or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a drug / drug composition as described above.
[0037] The isoprenic acid derivatives involved in this invention are synthesized using the methods disclosed in the reference (Angew. Chem. Int. Ed. 2023, 62, e2023076). Specific conditions such as reaction solvent, catalyst, and temperature can be adjusted according to actual needs.
[0038] The present invention has the following beneficial effects: the compounds or drugs / drug compositions of the present invention can increase LDLR protein levels, especially compound 1t, which shows a significant effect in reducing LDL-C levels through dual regulation of LDLR and PCSK9. It is suitable for the prevention and treatment of cardiovascular diseases caused by high LDL-C and is expected to serve as an alternative or complementary therapy to statins, especially for patients who are intolerant to or do not respond well to statins. It provides a new treatment option for cholesterol metabolism disorders such as hypercholesterolemia and atherosclerosis. Attached Figure Description
[0039] Figure 1 The inhibitory effect of the compounds of this invention on PCSK9 protein expression in HepG2 cells was demonstrated. The results showed that the inhibition of PCSK9 expression by the compounds of this invention was concentration-dependent.
[0040] Figure 2 A bar chart illustrating the quantitative analysis of the effect of the compounds of this invention on LDL-C uptake in HepG2 cells is presented. The results show that, compared with the DMSO control group, the compounds of this invention significantly increased LDL-C uptake in a concentration-dependent manner. Furthermore, the effects of the compounds of this invention on LDL-C uptake were comparable to those of berberine and rosuvastatin. Detailed Implementation
[0041] The present invention will be further described in detail below with reference to the specific embodiments and accompanying drawings. Except for the contents specifically mentioned below, the processes, conditions, and experimental methods for implementing the present invention are all common knowledge and general knowledge in the art, and the present invention does not have any particular limitations.
[0042] The following description of at least one exemplary embodiment is merely illustrative and is in no way intended to limit the invention or its application or use. All other embodiments obtained by those skilled in the art based on the embodiments of this invention without inventive effort are within the scope of protection of this invention.
[0043] In all examples shown and discussed herein, any specific values should be interpreted as merely exemplary and not as limitations. Therefore, other examples of exemplary embodiments may have different values.
[0044] The raw materials are commercially available, or prepared by methods known in the art, or prepared according to the methods described herein.
[0045] Example 1: Synthesis of compound 1a
[0046]
[0047] The synthetic route is as follows:
[0048]
[0049] Preparation of compound S2:
[0050] Under an argon atmosphere at 0°C, 11.2 mL of n-butyllithium was added dropwise to a 30 mL THF solution containing 2,2,6,6-tetramethylpiperidine (3.9339 g, 27.9 mmol). Then, a 55 mL THF solution containing bis[(pinacol)boryl]methane (7.5035 g, 28 mmol) was added to the reaction mixture. After 30 minutes, a 20 mL THF solution containing S1 (2.3630 g, 20 mmol) was added. After 3 hours, 20 mL of saturated ammonium chloride aqueous solution and 300 mL of water were added sequentially. The mixture was extracted three times with ethyl acetate. The organic phase was washed once with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, filtered, and the solvent was removed by rotary evaporation. The product S2 (3.5091 g, 86%) was purified by column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to give product S2 (3.5091 g, 86%): a pale yellow liquid. 1HNMR (400MHz, CDCl3): δ = 6.58 (dd, J1 = 18.0Hz, J2 = 6.0Hz, 1H), 5.38 (dd, J1 = 18.2Hz, J2 = 1 .4Hz,1H),2.09-1.97(m,1H),1.79-1.68(m,4H),1.68-1.60(m,1H),1.33-1.04(m,17H); 13 CNMR (100MHz, CDCl3): δ=159.8,82.9,43.2,31.9,26.1,25.9,24.7.
[0051] Preparation of compound S4:
[0052] Add Cp*Rh(OAc)2 (17.7 mg, 0.05 mmol), Cu(OAc)2·H2O (60.0 mg, 0.30 mmol), S2 (236.5 mg, 1.0 mmol), THF (10 mL), S3 (105.1 mg, 1.5 mmol), and H2O (54 μL) to a dry reaction flask. Stir at 50 °C for 23 hours. Filter the reaction mixture through silica gel, wash with ethyl acetate (40 mL), and remove the solvent by rotary evaporation. Separate and purify by column chromatography (eluent: petroleum ether / ethyl acetate = 30 / 1) to give product S4 (113.9 mg, 64%): a pale yellow liquid; 1 H NMR (400MHz, CDCl3): δ = 10.10 (d, J = 8.0Hz, 1H), 6.23 (dd, J1 = 15.6Hz, J2 = 6.4Hz, 1H), 6.16 (d, J=15.6Hz,1H),5.90(d,J=8.4Hz,1H),2.24(d,J=0.8Hz,3H),2.18-2.07(m,1H),1.80-1.73(m 4H),1.72-1.64(m,1H),1.38-1.07(m,5H); 13 C NMR (100MHz, CDCl3): δ=191.4,155.3,145.0,131.0,128.5,41.4,32.4,25.9,25.8,13.0.
[0053] Preparation of compound S5:
[0054] Under an argon atmosphere at 0°C, 4.5 mL of n-butyllithium was added dropwise to a THF solution containing 11.36 mL of 2,2,6,6-tetramethylpiperidine (1.9 mL, 11.36 mmol). After 0.5 hours, a THF solution containing 3.0448 g of 11.36 mmol of bis[(pinacol)boryl]methane (22.7 mL) was added. After 30 minutes, the reaction solution was cooled to -78°C, and a THF solution containing 1.2647 g of S4 (7.1 mmol) (7.1 mL) was added. After 3 hours, a saturated ammonium chloride aqueous solution (7 mL) and water (120 mL) were added sequentially, followed by extraction three times with ethyl acetate. The organic phase was washed once with a saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, filtered, and the solvent was removed by rotary evaporation. The product was separated and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1) to give product S5 (1.9735 g, 92%): a yellow liquid; 1 H NMR (400MHz, CDCl3): δ = 7.37 (dd, J1 = 17.6Hz, J2 = 11.2Hz, 1H), 6.14-6.01 (m, 2H), 5.76 (dd, J1 = 15.6Hz, J2 = 7.2Hz, 1H), 5.53 (d ,J=17.2Hz,1H),2.11-1.99(m,1H),1.93(s,3H),1.73(d,J=10.4Hz,4H),1.69-1.61(m,1H),1.28(s,14H),1.21-1.04(m,3H); 13 C NMR (100MHz, CDCl3): δ=145.8,139.4,138.1,132.0,131.1,83.1,41.2,33.0,26.1,26.0,24.7,13.1.
[0055] Preparation of compound S7:
[0056] Under dark conditions, S5 (3 mL, 1.5 mmol), S6 (342.9 mg, 2.25 mmol), THF (12 mL), and H2O (83.1 mg, 4.5 mmol) were added sequentially to a reaction tube containing Cp*Rh(OAc)2 (26.9 mg, 0.075 mmol) and Cu(OAc)2·H2O (90.1 mg, 0.45 mmol). After stirring at room temperature for 53 hours, the reaction mixture was filtered through silica gel, washed with ethyl acetate (40 mL), and the solvent was removed by rotary evaporation. The product was purified by column chromatography (eluent: petroleum ether / ethyl acetate = 60 / 1) to give product S7 (138.9 mg, 28%, 13E:13Z = 98:2): a yellow waxy liquid. 1H NMR (400MHz, CDCl3): δ = 10.01 (d, J = 8.4Hz, 1H), 7.08 (dd, J1 = 15.2Hz, J2 = 11.2Hz, 1H),6.25(d,J=15.2Hz,1H),6.13(d,J=14.8Hz,2H),6.02(d,J=8.4Hz,1H),5.83( dd,J1=15.6Hz, J2=7.2Hz,1H),2.63(d,J=6.8Hz,2H),2.13-2.03(m,1H),1.95(s, 3H),1.80-1.62(m,11H),1.55-1.45(m,1H),1.36-1.04(m,9H),1.05-0.93(m,2H); 13 C NMR (100MHz, CDCl3): δ=191.2,158.4,141.0,139.0,133.7,132.5,131.9, 129.2,128.8,41.3,39.0,34.9,33.6,32.9,26.3,26.2,26.0,25.9,13.2.
[0057] Preparation of compound 1a:
[0058] S7 (98.2 mg, 0.3 mmol, 13E:13Z = 98:2) and tert-butanol (6 mL), and 2-methyl-2-butene (1.8 mL, 15 mmol) were added sequentially to a dry reaction tube. An aqueous solution (3 mL) containing NaClO2 (237.9 mg) and NaH2PO4 (251.9 mg) was added dropwise to the reaction mixture. After stirring at room temperature for 13 hours, water (10 mL) was added, and the mixture was extracted four times with diethyl ether. The extract was dried over anhydrous sodium sulfate, filtered, and the solvent was removed by rotary evaporation. The product was purified by column chromatography (eluent: petroleum ether / acetone = 20 / 1), and recrystallized to give product 1a (42.8 mg, 42%): a white solid. 1 H NMR (400MHz, CDCl3): δ=7.00 (dd, J1=15.2Hz, J2=11.2Hz, 1H,=CH), 6.21 (d, J=15.2Hz, 1H,=CH), 6.17-6.05 (m, 2H, 2x=C H),5.84-5.74(m,2H,2x=CH),2.80(d,J=6.8Hz,2H,CH2),2.11-2.01(m,1H,CH),1.94(s,3H,CH3),1.79-1.59(m,10H,5x CH2),1.56-1.46(m,1H,CH),1.35-0.99(m,10H,5x CH2); 13C NMR (100MHz, CDCl3): δ=171.9,159.2,139.9,138.4,134.5,132.0,131.8,128.9,117.4,41.3,39.0,34.9,33.5,33.0,26.4 ,26.4,26.1,26.0,13.1; IR(neat):v=2920,2847,1669,1577,1562,1445,1410,1276,1259,1242,1206,1182,1156,1114cm -1 MS (70eV, EI) m / z (%): 342 (M + ,13.79),105(100); HRMS(EI)calcd m / z for C 23 H 34 O2[M + ]: 342.2553, found 342.2556; HPLC purity: 98.1%.
[0059] The compounds described in Examples 2-27 can be prepared by referring to the method and route described in Example 1 of this invention.
[0060] Example 2: Synthesis of compound 1b
[0061]
[0062] Yellow solid; 1 H NMR (400MHz, CDCl3): δ=7.00 (dd, J1=14.8Hz, J2=11.2Hz, 1H,=CH), 6.21 (d, J=15.2Hz, 1H,=CH), 6.15 (d, J=15.6Hz, 1H,=CH), 6.10 (d, J=11.2Hz, 1H,=C H),5.89-5.76(m,2H,2x=CH),2.80(d,J=6.8Hz,2H,CH2),2.53(sext,J=8.0Hz,1H,CH),1.95(s,3H,CH3),1.88-1.78(m,2H,CH2),1.75-1.64(m,6H,3x CH2),1.64-1.47(m,4H,2xCH2),1.39-1.28(m,2H,CH2),1.23-1.11(m,3H,CH2 and CH),1.10-0.98(m,2H,CH2); 13CNMR (100MHz, CDCl3): δ=171.8,159.2,139.7,137.3,134.5,132.6,131.8,128.8,117.4,43.9,39.0,33.5,33.4,26. 5,26.4,25.2,13.2; IR(neat):v=2918,2848,1668,1575,1561,1446,1412,1284,1259,1242,1205,1182,1157,1115cm -1 MS (70eV, EI) m / z (%): 328 (M + ,69.2),105(100); HRMS(EI)calcd m / z for C 22 H 32 O2[M + ]:328.2397, found 328.2403; HPLCpurity:99.5%.
[0063] Example 3: Synthesis of compound 1c
[0064]
[0065] Yellow solid; 1 H NMR (400MHz, CDCl3): δ=7.00 (dd, J1=14.8Hz, J2=11.2Hz, 1H,=CH), 6.21 (d, J=15.2Hz, 1H,=CH), 6.14-6.06 (m, 2H, 2x=CH) ,5.89-5.78(m,2H,2x=CH),2.80(d,J=7.2Hz,2H,CH2),2.32-2.21(m,1H,CH),1.94(s,3H,CH3),1.81-1.58(m,11H,5xCH2 and one proton ofCH2),1.56-1.43(m,5H,2x CH2 and one proton ofCH2),1.41-1.32(m,2H,CH2),1.25-1.11(m,3H,CH2 and CH),1.10-0.97(m,2H,CH2); 13C NMR (100MHz, CDCl3): δ=172.1,159.2,140.0,139.2,134.4,131.8,131.5,128.8,117.4,43.3,39.0,34.9,34.8,33.5,28.4 ,26.5,26.4,26.2,13.2; IR(neat):v=2919,2848,1670,1575,1562,1444,1410,1284,1259,1242,1207,1181,1157,1114cm -1 MS (70eV, EI) m / z (%): 356 (M + ,28.96),207(100); HRMS(EI)calcd m / z for C 24 H 36 O2[M + ]:356.2710, found 356.2715; HPLCpurity:98.7%.
[0066] Example 4: Synthesis of compound 1d
[0067]
[0068] White solid; 1 H NMR (400MHz, CDCl3): δ = 6.99 (dd, J1 = 15.2Hz, J2 = 11.6Hz, 1H, = CH), 6.23 (d, J = 15.2Hz, 1H ,=CH),6.19-6.09(m,2H,2x=CH),5.82(s,1H,=CH),5.76(dd,J1=15.6Hz,J2=6.8Hz,1H,=C H),3.99(dd,J1=11.6Hz,J2=2.4Hz,2H,OCH2),3.44(td,J1=12.0Hz,J2=2.0Hz,2H,OCH2) ,2.80(d,J=6.8Hz,2H,CH2),2.39-2.27(m,1H,CH),1.95(s,3H,CH3),1.75-1.59(m,8H,4x CH2),1.58-1.44(m,4H,2x CH2),1.23-1.11(m,3H,CH2 andCH),1.10-0.97(m,2H,CH2); 13C NMR (100MHz, CDCl3): δ=170.7,159.0,139.3,135.8,135.0,132.9,131.5,129.6,117.4,67.7,38.9,38.5,34.9,3 3.5,32.7,26.5,26.4,13.1; IR(neat):v=2921,2847,1668,1578,1411,1258,1241,1206,1183,1156,1125,1086cm -1 MS (70eV, EI) m / z (%): 344 (M + ,6.41),105(100); HRMS(EI)calcd m / z for C 22 H 32 O3[M + ]: 344.2346, found344.2345; HPLC purity: 99.2%.
[0069] Example 5: Synthesis of compound 1e
[0070]
[0071] Yellow solid; 1 H NMR (400MHz, CDCl3): δ = 7.45 (d, J = 7.6Hz, 2H, Ar-H), 7.33 (t, J = 7.6Hz, 2H, Ar-H), 7.24 (t,J=7.2Hz,1H,Ar-H),7.06(dd,J1=15.2Hz,J2=11.6Hz,1H,=CH),6.90(d,J=16.0Hz,1 H,=CH),6.69(d,J=16.0Hz,1H,=CH),6.38-6.26(m,2H,2x=CH),5.85(s,1H,=CH),2.83( d,J=7.2Hz,2H,CH2),2.08(s,3H,CH3),1.78-1.67(m,4H,2xCH2),1.66-1.60(m,1H,one proton ofCH2),1.58-1.48(m,1H,one proton of CH2),1.27-1.13(m,3H,CH2 and CH),1.12-0.99(m,2H,CH2); 13C NMR (100MHz, CDCl3): δ=172.2,159.0,139.5,137.4,135.8,133.0,131.8,131.5,129.6,128.7,127.7,126.6,118.2,39.0,35.0 ,33.5,26.5,26.4,13.2; IR(neat):v=2917,2844,1665,1591,1561,1445,1421,1322,1291,1243,1207,1182,1149,1117,1068cm -1 MS (70eV, EI) m / z (%): 336 (M + ,96.97),248(100); HRMS(EI)calcd m / z for C 23 H 28 O2[M + ]: 336.2084, found 336.2083; HPLC purity: 99.8%.
[0072] Example 6: Synthesis of compound 1f
[0073]
[0074] Yellow solid; 1 H NMR (400MHz, CDCl3): δ=7.30-7.20(m,3H,Ar-H),7.12-7.00(m,2H,Ar-H and=CH),6.89(d,J=16.0Hz,1H,=CH),6.66(d,J=16.0Hz,1H,=CH),6.38-6.23(m,2H,2x=CH),5.8 5(s,1H,=CH),2.83(d,J=7.2Hz,2H,CH2),2.36(s,3H,CH3),2.07(s,3H,CH3),1.78-1.67(m,4H,2x CH2),1.66-1.60(m,1H,one proton ofCH2),1.59-1.48(m,1H,one proton ofCH2),1.27-1.13(m,3H,CH2 and CH),1.12-1.00(m,2H,CH2); 13C NMR (100MHz, CDCl3): δ=172.1,159.0,139.5,138.2,137.2,135.6,132.8,131.5,131.5,129.7,128.6,128.5,127.3,123.8,118.1,39.0,3 4.9,33.5,26.4,26.4,21.4,13.1; IR(neat):v=2925,2845,1673,1597,1561,1446,1413,1360,1343,1319,1277,1257,1207,1184,1147cm -1 MS (70eV, EI) m / z (%): 350 (M + ,97.05),207(100); HRMS(EI)calcd m / z forC 24 H 30 O2[M + ]: 350.2240, found 350.2240; HPLC purity: 99.9%.
[0075] Example 7: Synthesis of 1g of compound
[0076]
[0077] Yellow solid; 1 H NMR (400MHz, CDCl3): δ = 7.45 (s, 1H, Ar-H), 7.32-7.27 (m, 3H, Ar-H), 7.06 (dd, J1 = 15.2Hz, J2 = 11.6Hz, 1H, = CH), 6.90 (d, J = 16.0Hz, 1H, = CH), 6.71 (d, J = 16. 0Hz,1H,=CH),6.35(d,J=11.6Hz,1H,=CH),6.30(d,J=15.2Hz,1H,=CH),5.85( s,1H,=CH),2.83(d,J=6.8Hz,2H,CH2),2.09(s,3H,CH3),1.78-1.67(m,4H,2x CH2),1.66-1.61(m,1H,one proton ofCH2),1.58-1.51(m,1H,one proton ofCH2),1.35(s,9H,3xCH3),1.24-1.14(m,3H,CH2 and CH),1.12-1.01(m,2H,CH2); 13C NMR (100MHz, CDCl3): δ=171.7,159.0,151.5,139.6,137.0,135.6,132.7,131.5,131.5,130.1,128.4,125.0,124.0,123.5,117.9,39.0,34.9,3 4.7,33.5,31.3,26.5,26.4,13.1;IR(neat):v=2917,2843,1673,1596, 1564,1448,1410,1359,1283,1263,1243,1208,1183,1157,1116,1066cm -1 MS (70eV, EI) m / z (%): 392 (M + ,27.04),207(100); HRMS(EI)calcd m / z for C 27 H 36 O2[M + ]: 392.2710, found 392.2711; HPLC purity: 99.3%.
[0078] Example 8: Synthesis of compound 1h
[0079]
[0080] Yellow solid; 1 H NMR (400MHz, CDCl3): δ = 7.34 (s, 1H, Ar-H), 7.30 (s, 2H, Ar-H), 7.07 (dd, J1 = 14.8Hz, J2 = 11.2Hz, 1H, = CH), 6.90 (d, J = 16.0Hz, 1H, = CH), 6.73 (d, J = 16.0Hz ,1H,=CH),6.36(d,J=11.6Hz,1H,=CH),6.30(d,J=15.2Hz,1H,=CH),5.85(s ,1H,=CH),2.83(d,J=6.8Hz,2H,CH2),2.10(s,3H,CH3),1.79-1.68(m,4H,2x CH2),1.67-1.60(m,1H,one proton ofCH2),1.60-1.51(m,1H,one proton ofCH2),1.35(s,18H,6x CH3),1.26-1.14(m,3H,CH2 and CH),1.12-1.01(m,2H,CH2); 13C NMR (100MHz, CDCl3): δ=172.2,159.0,151.1,139.7,136.5,135.4,132.3,131.6,131.3,130.7,122.3,120.9,118.0,39.0,34.9,34.8,33.5 ,31.4,26.5,26.4,13.2; IR(neat):v=2956,2919,2847,1675,1590,1564,1451,1415,1362,1320,1287,1262,1247,1212,1185,1156,1118cm -1 MS (70eV, EI) m / z (%): 448 (M + ,5.04),207(100); HRMS(EI)calcd m / z for C 31 H 44 O2[M + ]: 448.3336, found 448.3337; HPLC purity: 98.8%.
[0081] Example 9: Synthesis of Compound 1i
[0082]
[0083] Yellow liquid; 1 H NMR (400MHz, CDCl3): δ = 7.07 (dd, J1 = 14.8Hz, J2 = 11.2Hz, 1H, = CH), 6.71 (d, J = 16.4Hz, 1H ,=CH),6.60(s,1H,Ar-H),6.28(d,J=4.8Hz,1H,=CH),6.24(d,J=6.0Hz,1H,=CH),6.20(d ,J=11.2Hz,1H,=CH),5.83(s,1H,=CH),3.82(s,3H,OCH3),2.83(d,J=6.8Hz,2H,CH2),2. 30(s,3H,CH3),2.24(s,3H,CH3),2.15(s,3H,CH3),2.11(s,3H,CH3),1.78-1.67(m,4H,2x CH2),1.66-1.60(m,1H,one proton ofCH2),1.59-1.49(m,1H,one proton of CH2),1.27-1.13(m,3H,CH2 and CH),1.12-1.00(m,2H,CH2); 13C NMR (100MHz, CDCl3): δ=172.2,159.0,156.2,139.6,138.1,135.9,135.3 ,133.9,131.5,130.4,129.8,128.8,122.7,117.9,109.9,55.5,39.0,34. 9,33.5,26.5,26.4,21.4,17.4,13.0,11.8; IR(neat):v=2919,2848,1670 ,1561,1462,1448,1410,1309,1282,1261,1243,1206,1182,1153,1118cm -1 MS(ESI) m / z: 409([M+H] + ); HRMS(ESI)calcd for C 27 H 37 O3([M+H)) + ):409.2737, found409.2737; HPLC purity:99.0%.
[0084] Example 10: Synthesis of Compound 1j
[0085]
[0086] Yellow solid; 1 H NMR (400MHz, CDCl3): δ = 7.34 (s, 1H, Ar-H), 7.20 (dd, J1 = 15.6Hz, J2 = 8.0Hz, 2H, Ar-H), 7.06 (dd, J1 = 15.2Hz, J2 = 11.6Hz, 1H, = C H),6.86(d,J=16.0Hz,1H,=CH),6.69(d,J=16.0Hz,1H,=CH),6.35-6.24(m,2H,2x=CH),5.85(s,1H,=CH),2.95-2.87(m,4H,2x CH2),2.82(d,J=6.8Hz,2H,CH2),2.13-2.04(m,5H,CH3 and CH2),1.78-1.67(m,4H,2x CH2),1.66-1.60(m,1H,one proton of CH2),1.58-1.49(m,1H,one proton ofCH2),1.27-1.13(m,3H,CH2 and CH),1.12-1.00(m,2H,CH2); 13C NMR (100MHz, CDCl3): δ=170.8,159.0,144.9,144.3,139.8,135.5,135.3,131.9,131.6,131.1,130.1,125.1,124.6,122.2,117.5,39.0,3 4.9,33.5,32.7,26.5,26.4,25.5,13.1; IR(neat):v=2917,2847,1669,1595,1560,1439,1411,1280,1259,1242,1203,1180,1157,1114cm -1 MS (70eV, EI) m / z (%): 376 (M + ,62.17),235(100); HRMS(EI)calcd m / z for C 26 H 32 O2[M + ]: 376.2397, found 376.2398; HPLC purity: 99.4%.
[0087] Example 11: Synthesis of compound 1k
[0088]
[0089] White solid; 1 H NMR (400MHz, CDCl3): δ = 6.62 (d, J = 16.0Hz, 1H, = CH), 6.14 (d, J = 16.0Hz, 1H, = CH), 5.77 (s, 1H, = CH), 2.35 (s, 3H, C H3),2.03(t,J=6.0Hz,2H,CH2),1.71(s,3H,CH3),1.66-1.57(m,2H,CH2),1.51-1.44(m,2H,CH2),1.03(s,6H,2x CH3); 13 C NMR (100MHz, CDCl3): δ=172.9,155.4,137.1,136.0,134.7,131.6,117.3,39.5,34.2,33.0,28.9, 21.7,19.0,13.8; IR(neat):v=2960,2921,2904,2853,1679,1595,1438,1376,1351,1251,1185cm -1 MS (70eV, EI) m / z (%): 234 (M + ,41),119(100);HRMS(EI)calcd m / z forC15 H 22 O2[M + ]: 234.1614, found 234.1615; HPLC purity: 99.1%.
[0090] Example 12: Synthesis of Compound 11
[0091]
[0092] Red solid; 1 H NMR (400MHz, CDCl3): δ = 7.04 (dd, J1 = 14.8Hz, J2 = 12.0Hz, 1H, = CH), 6.75 (dd, J1 = 14.8Hz, J2 = 12.0Hz, 1H, = CH), 6.35 (dd, J 1=14.4Hz,J2=9.6Hz,2H,2x=CH),6.28-6.08(m,4H,4x=CH),5.81(s,1H,=CH),2.37(s,3H,CH3),2.07-2.00(m,5H,CH3and CH2),1.99(s,3H,CH3),1.72(s,3H,CH3),1.65-1.58(m,2H,CH2),1.51-1.44(m,2H,CH2),1.03(s,6H,2x CH3); 13 C NMR (100MHz, CDCl3): δ=172.1,155.2,140.4,137.8,137.6,137.3,136.6,135.4,131.8,130.8,130.4,129.6,127.4,126.9,117.8,39. 6,34.2,33.1,28.9,21.7,19.2,14.0,13.1,12.8; IR(neat):v=2924,2862,1683,1593,1546,1395,1359,1251,1185,1162,1026,1006cm -1 MS(ESI)m / z:367([M+H] + ); HRMS(ESI)calcd for C 25 H 35 O2([M+H)) + ): 367.2628, found 367.2632; HPLC purity: 95.1%.
[0093] Example 13: Synthesis of compound 1m
[0094]
[0095] Yellow solid; 1 H NMR (400MHz, CDCl3): δ=7.06 (dd, J1=15.2Hz, J2=11.6Hz, 1H,=CH), 6.30 (d, J=16.0Hz, 1H,=CH), 6.22 (d, J=15. 2Hz,1H,=CH),6.19-6.10(m,2H,2x=CH),5.74(s,1H,=CH),2.88(q,J=7.5Hz,2H,CH2),2.06-1.97(m,5H,CH3and CH2),1.72(s,3H,CH3),1.65-1.59(m,2H,CH2),1.50-1.45(m,2H,CH2),1.15(t,J=7.6Hz,3H,CH3),1.03(s,6H,2x CH3); 13 C NMR (100MHz, CDCl3): δ=171.0,161.7,140.1,137.7,137.3,133.6,131.5,130.2,129.6,129.0,116.4,39.6,34.3,33.1,29. 0,21.8,21.1,19.2,14.3,13.0; IR(neat):v=2957,2926,2864,1678,1602,1566,1413,1357,1278,1232,1183,1159,1076cm -1 MS (70eV, EI) m / z (%): 314 (M + ,39.0),105(100); HRMS(EI)calcd m / z for C 21 H 30 O2[M + ]: 314.224, found314.2241; HPLC purity: 99.3%.
[0096] Example 14: Synthesis of compound 1n
[0097]
[0098] Orange liquid; 1H NMR (400MHz, CDCl3): δ = 7.14 (dd, J1 = 15.2Hz, J2 = 11.6Hz, 1H, = CH), 6.39-6.28 (m, 2H, 2x = CH), 6.20-5.82 (m, 4H, CF2H and 3x=CH),3.46(td,J1=16.1Hz,J2=4.5Hz,2H,CH2),2.06-2.00(m,5H,CH3 and CH2),1.72(s,3H,CH3),1.66-1.58(m,2H,CH2),1.50-1.44(m,2H,CH2),1.03(s,6H,2x CH3); 13 C NMR (100MHz, CDCl3): δ = 171.2, 150.2 (t, J = 6.1Hz), 141.8, 137.6, 137.0, 133.6, 133.0, 130.5, 129.9 ,129.2,119.2,116.1(t,J=241.0Hz),39.6,34.3,33.1,33.0(t,J=23.5Hz),28.9,21.7,19.2,13.0; 19 F NMR (376MHz, CDCl3): δ = -113.4; IR (neat): v = 3200-2300 (br), 1678, 1605, 1568, 1441, 1411, 1389, 1362, 1265, 1221, 1156, 1111, 1056cm -1 MS(ESI)m / z:349([MH]) - ); HRMS(ESI)calcdfor C 21 H 29 F2O2([M+H)) + ): 351.2130, found 351.2128; HPLC purity: 96.2%.
[0099] Example 15: Synthesis of Compound 1o
[0100]
[0101] Orange liquid; 1H NMR (400MHz, CDCl3): δ = 7.08 (dd, J1 = 14.8Hz, J2 = 11.2Hz, 1H, = CH), 6.41-6.29 (m, 2H, 2x = CH), 6.24-6.11(m,2H,2x=CH),6.04(s,1H,=CH),3.90(q,J=10.4Hz,2H,CH2),2.09-1.98(m,5H,CH3 and CH2),1.72(s,3H,CH3),1.66-1.59(m,2H,CH2),1.51-1.44(m,2H,CH2),1.03(s,6H,2x CH3); 13 C NMR (100MHz, CDCl3): δ = 170.8, 146.6 (q, J = 2.6Hz), 141.7, 137.6, 137.0, 133.3, 132.2, 130.5, 130.0 ,129.1,125.2(q,J=276.5Hz),120.9,39.6,34.3,33.1,31.3(q,J=30.3Hz),28.9,21.7,19.2,13.0; 19 FNMR (376MHz, CDCl3): δ = -63.3; IR (neat): v = 2927, 2865, 1681, 1607, 1570, 1440, 1412, 1360, 1340, 1251, 1189, 1139, 1090cm -1 MS (70eV, EI) m / z (%): 368 (M + ,58.54),105(100); HRMS(EI)calcd m / z for C 21 H 27 F3O2[M + ]: 368.1958, found 368.1961; HPLC purity: 95.1%.
[0102] Example 16: Synthesis of compound 1p
[0103]
[0104] Yellow solid; 1H NMR (400MHz, CDCl3): δ=7.06 (dd, J1=14.8Hz, J2=11.2Hz, 1H,=CH), 6.26 (d, J=12.4Hz, 1H,=CH), 6.19 (d, J=13 .2Hz,1H,=CH),6.20-6.10(m,2H,2x=CH),5.76(s,1H,=CH),2.92-2.82(m,2H,CH2),2.07-1.98(m,5H,CH3and CH2),1.72(s,3H,CH3),1.65-1.59(m,2H,CH2),1.53-1.41(m,6H,3x CH2),1.03(s,6H,2x CH3),0.95(t,J=7.2Hz,3H,CH3); 13 C NMR (100MHz, CDCl3): δ=171.9,160.5,140.1,137.7,137.2,134.0,131.5,130.1,129.6,129.0,116.8,39.6,34.2,33.1,32.0,29.0,28.9,27. 5,23.0,21.7,19.2,13.9,12.9; IR(neat):v=2958,2925,2856,1676,1600,1564,1458,1411,1358,1298,1258,1247,1211,1179,1157,1093cm -1 MS (70eV, EI) m / z (%): 342 (M + ,35.0),105(100); HRMS(EI)calcd m / z for C 23 H 34 O2[M + ]: 342.2553, found 342.2553; HPLC purity: 98.1%.
[0105] Example 17: Synthesis of compound 1q
[0106]
[0107] Yellow solid; 1H NMR (400MHz, CDCl3): δ=7.06 (dd, J1=14.8Hz, J2=11.2Hz, 1H,=CH), 6.30 (d, J=16.0Hz, 1H,=CH), 6.22 (d, J=15 .2Hz,1H,=CH),6.19-6.10(m,2H,2x=CH),5.75(s,1H,=CH),2.92-2.79(m,2H,CH2),2.07-1.99(m,5H,CH3and CH2),1.72(s,3H,CH3),1.66-1.58(m,2H,CH2),1.54-1.45(m,4H,2x CH2),1.45-1.38(m,2H,CH2),1.36-1.29(m,4H,2x CH2),1.03(s,6H,2x CH3),0.93-0.87(m,3H,CH3); 13 C NMR (100MHz, CDCl3): δ=172.2,160.5,140.1,137.7,137.2,134.0,131.5,130.1,129.6,129.0,117.0,39.6,34.2,33.1,31.5,29.8,29.5, 29.0,27.8,22.5,21.7,19.2,14.1,12.9; IR(neat):v=2952,2925,2863,1672,1602,1571,1455,1412,1358,1279,1262,1242,1193,1157cm -1 MS (70eV, EI) m / z (%): 370 (M + ,77.16),105(100); HRMS(EI)calcd m / z for C 25 H 38 O2[M + ]: 370.2866, found370.2866; HPLC purity: 97.9%.
[0108] Example 18: Synthesis of compound 1r
[0109]
[0110] Yellow solid; 1H NMR (400MHz, CDCl3): δ=7.07 (dd, J1=14.8Hz, J2=11.6Hz, 1H,=CH), 6.30 (d, J=16.0Hz, 1H,=CH), 6.22 (d, J=15 .2Hz,1H,=CH),6.19-6.10(m,2H,2x=CH),5.74(s,1H,=CH),2.93-2.76(m,2H,CH2),2.07-1.95(m,5H,CH3and CH2),1.71(s,3H,CH3),1.66-1.58(m,2H,CH2),1.51-1.45(m,2H,CH2),1.42-1.35(m,2H,CH2),1.03(s,6H,2xCH3),0.99(s,9H,3x CH3); 13 C NMR (100MHz, CDCl3): δ=171.5,161.0,140.2,137.7,137.2,133.8,131.5,130.1,129.5,129.0,116.7,43.7,39.6,34.2,33.1,30.9,29. 1,28.9,23.6,21.7,19.2,12.8; IR(neat):v=2952,2923,2861,1673,1597,1559,1461,1412,1363,1281,1262,1237,1190,1161,1130cm -1 MS (70eV, EI) m / z (%): 370 (M + ,24.2),57(100);HRMS(EI)calcd m / zfor C 25 H 38 O2[M + ]: 370.2866, found 370.2866; HPLC purity: 97.7%.
[0111] Example 19: Synthesis of Compound 1s
[0112]
[0113] Yellow solid; 1H NMR (400MHz, CDCl3): δ = 7.07 (dd, J1 = 14.8Hz, J2 = 11.2Hz, 1H, = CH), 6.34-6.21 (m, 2H, 2x = CH), 6. 20-6.10(m,2H,2x=CH),5.79(s,1H,=CH),2.95(d,J=7.6Hz,2H,CH2),2.10-1.96(m,6H,CH3,CH2 and one proton ofCH2),1.75-1.59(m,9H,CH3and3x CH2),1.53-1.44(m,4H,2x CH2),1.30-1.22(m,2H,one proton ofCH2 and CH),1.03(s,6H,2x CH3); 13 C NMR (100MHz, CDCl3): δ=172.1,160.0,140.0,137.7,137.2,134.4,131.7,130.1,129.6,129.0,117.1,41.0,39.6,34.2,33.1, 32.6,32.5,28.9,24.7,21.7,19.2,13.0; IR(neat):v=2942,2866,1671,1561,1451,1411,1360,1257,1217,1184,1161,1130cm -1 MS (70eV, EI) m / z (%): 368 (M + ,36.72),145(100); HRMS(EI)calcd m / z forC 25 H 36 O2[M + ]: 368.2710, found 368.2709; HPLC purity: 96.6%.
[0114] Example 20: Synthesis of compound 1t
[0115]
[0116] Yellow solid; 1H NMR (400MHz, CDCl3): δ = 7.04 (dd, J1 = 14.8Hz, J2 = 11.6Hz, 1H, = CH), 6.35-6.21 (m, 2H, 2x = CH), 6.20-6.10(m,2H,2x=CH),5.82(s,1H,=CH),2.81(d,J=7.2Hz,2H,CH2),2.09-1.97(m,5H,CH3 and CH2),1.76-1.66(m,7H,CH3 and 2x CH2),1.65-1.58(m,3H,one proton ofCH2 and CH2),1.53-1.43(m,3H,one proton ofCH2 and CH2),1.21-1.14(m,3H,CH2 and CH),1.10-0.99(m,8H,2x CH3 and CH2); 13 C NMR (100MHz, CDCl3): δ=171.7,159.2,140.0,137.7,137.2,134.7,131.7,130.1,129.6,129.0,117.4,39.6,39.0,34.9,34.2,33.5,33.1, 28.9,26.5,26.4,21.7,19.2,13.0; IR(neat):v=2923,2850,1667,1588,1552,1449,1409,1360,1283,1257,1242,1203,1178,1158,1116cm -1 MS (70eV, EI) m / z (%): 382 (M + ,10.16),55(100); HRMS(EI)calcd m / z for C 26 H 38 O2[M + ]: 382.2866, found 382.2868; HPLC purity: 97.2%.
[0117] Example 21: Synthesis of compound 1u
[0118]
[0119] Yellow liquid; 1¹H NMR (400 MHz, CDCl₃): δ = 7.08 (dd, J₁ = 15.2 Hz, J₂ = 11.6 Hz, 1H, =CH), 6.31 (d, J = 16.4 Hz, 1H, =CH), 6.26 (d, J = 15.2 Hz, 1H, =CH), 6.20-6.10 (m, 2H, 2×=CH), 5.83 (s, 1H, =CH), 3.97-3.90 (m, 1H, one proton of OCH₂), 3.86 (t, J = 7.6 Hz, 1H, one proton of OCH₂), 3.77 (q, J = 7.6 Hz, 1H, one proton of OCH₂), 3.52 (t, J = 7.6 Hz, 1H, one proton of OCH₂), 3.08 (dd, J₁ = 12.8 Hz, J₂ = 8.0 Hz, 1H, one proton of CH₂), 2.93 (dd, J₁ = 12.4 Hz, J₂ = 7.2 Hz, 1H, one proton of CH₂), 2.49 (sept, J = 7.2 Hz, 1H, CH), 2.05-1.95 (m, 6H, CH₃, CH₂ and one proton of CH₂), 1.75-1.67 (m, 4H, CH₃ and one proton of CH₂), 1.65-1.59 (m, 2H, CH₂), 1.50-1.44 (m, 2H, CH₂), 1.03 (s, 6H, 2× CH₃); 13 ¹³C NMR (100 MHz, CDCl₃): δ = 171.5, 158.1, 140.6, 137.7, 137.1, 133.9, 131.9, 130.2, 129.3, 129.3, 117.7, 72.8, 67.8, 39.8, 39.6, 34.2, 33.1, 31.9, 29.8, 28.9, 24.8, 21.7, 19.2, 13.0; IR (neat): ν = 2924, 2863, 1675, 1602, 1571, 1451, 1411, 1359, 1260, 1196, 1177, 1153 cm -1 ; MS (ESI) m / z: 371 ([M+H] + ); HRMS (ESI) calcd for C 24 H 35 O₃ ([M+H] + ): 371.2581, found 371.2571; HPLC purity: 97.3%.
[0120] Example 22: Synthesis of compound 1v
[0121]
[0122] Yellow liquid; 1 H NMR (400MHz, CDCl3): δ = 7.06 (dd, J1 = 15.2Hz, J2 = 11.6Hz, 1H, = CH), 6.39-6.23 (m, 2H, 2x = CH), 6.22-6.09 (m, 2H, 2x = CH), 5.84 (s, 1 H,=CH),3.96(dd,J1=10.8Hz,J2=2.8Hz,2H,OCH2),3.35(t,J=11.0Hz,2H,OCH2),2.87(d,J=7.2Hz,2H,CH2),2.10-1.95(m,5H,CH3 and CH2),1.85-1.77(m,1H,CH),1.72(s,3H,CH3),1.66-1.57(m,4H,2x CH2),1.51-1.42(m,4H,2x CH2),1.03(s,6H,2x CH3); 13 C NMR (100MHz, CDCl3): δ=171.7,158.0,140.4,137.7,137.1,134.4,131.9,130.2,129.4,129.3,117.9,68.1,39.5,36.1,34.2,33.2,33. 1,28.9,21.7,19.2,13.0; IR(neat):v=2927,2860,1675,1602,1565,1451,1411,1387,1359,1252,1235,1206,1154,1132,1087,1015cm -1 MS (70eV, EI) m / z (%): 384 (M + ,20.32),207(100); HRMS(EI)calcd m / z for C 25 H 36 O3[M + ]: 384.2659, found384.2660; HPLC purity: 98.2%.
[0123] Example 23: Synthesis of compound 1w
[0124]
[0125] Yellow solid; 1H NMR (400MHz, CDCl3): δ=7.28-7.22(m,4H,Ar-H),7.20-7.14(m,1H,Ar-H),7.04(dd,J 1=15.2Hz, J2=11.2Hz, 1H,=CH), 6.25(d, J=15.2Hz, 2H, 2x=CH), 6.12-6.04(m, 2H, 2x=C H),5.97(s,1H,=CH),4.32(s,2H,CH2),2.00(t,J=6.0Hz,2H,CH2),1.87(s,3H,CH3), 1.68(s,3H,CH3),1.64-1.55(m,2H,CH2),1.48-1.42(m,2H,CH2),1.00(s,6H,2xCH3); 13 C NMR (100MHz, CDCl3): δ=171.7,156.8,140.5,139.1,137.7,137.1,133.4,133.3,130.1,129.4,129.2,128.5,128.2,126.0,118.2,39.6,3 4.2,33.4,33.1,28.9,21.7,19.2,12.8; IR(neat):v=2927,2864,1676,1602,1575,1495,1451,1413,1374,1241,1206,1146,1075,1044cm -1 MS (70eV, EI) m / z (%): 376 (M + ,5.47),91(100);HRMS(EI)calcd m / zforC 26 H 32 O2[M + ]: 376.2397, found 376.2397; HPLC purity: 98.2%.
[0126] Example 24: Synthesis of compound 1x
[0127]
[0128] Yellow solid; 1H NMR (400MHz, CDCl3): δ = 7.30 (d, J = 14.8Hz, 2H, oxole-H), 7.14 (dd, J1 = 15.2Hz, J2 = 11.6Hz, 1H, = CH), 6.35-6.23 (m, 3H, oxole-H and 2x=CH),6.18-6.09(m,2H,2x=CH),5.87(s,1H,=CH),4.06(s,2H,CH2),2.02(t,J=5.8Hz,2H,CH2),1. 97(s,3H,CH3),1.71(s,3H,CH3),1.65-1.57(m,2H,CH2),1.49-1.43(m,2H,CH2),1.02(s,6H,2xCH3); 13 C NMR (100MHz, CDCl3): δ=172.0,157.0,142.6,140.7,139.7,137.7,137.1,133.1,132.8,130.2,129.3,122.4,117.4,111.1,39.6,34.2,3 3.1,28.9,23.2,21.7,19.2,12.9; IR(neat):v=3040,2922,1675,1596,1555,1444,1402,1357,1283,1249,1197,1160,1129,1068,1024cm -1 MS (70eV, EI) m / z (%): 366 (M + ,21.0),81(100);HRMS(EI)calcd m / z forC 24 H 30 O3[M + ]: 366.2189, found 366.2189; HPLC purity: 96.2%.
[0129] Example 25: Synthesis of compound 1y
[0130]
[0131] Yellow solid; 1H NMR (400MHz, CDCl3): δ=7.22 (dd, J1=4.8Hz, J2=3.2Hz, 1H, thiophene-H), 7.11 (dd, J1=14. 8Hz, J2=11.6Hz,1H,=CH),7.05-6.92(m,2H,thiophene-H),6.34-6.20(m,2H,2x=CH),6.12( d,J=15.2Hz,1H,=CH),5.90(s,1H,=CH),4.28(s,2H,CH2),2.02(t,J=5.8Hz,2H,CH2),1.93( s,3H,CH3),1.70(s,3H,CH3),1.65-1.56(m,2H,CH2),1.50-1.42(m,2H,CH2),1.01(s,6H,2x CH3); 13 C NMR (100MHz, CDCl3): δ=171.5,156.9,140.7,139.1,137.7,137.1,133.3,13 3.0,130.2,129.4,129.3,128.2,125.2,121.1,117.4,39.6,34.2,33.1,28. 9,28.4,21.7,19.2,12.9;IR(neat):v=3484,2972,2939,2890,1673,1600,1 562,1444,1408,1381,1358,1292,1263,1233,1195,1158,1134,1089,1046cm -1 MS (70eV, EI) m / z (%): 382 (M + ,38.13),97(100);HRMS(EI)calcd m / z forC 24 H 30 O2S[M + ]: 382.1961, found 382.1960; HPLC purity: 99.4%.
[0132] Example 26: Synthesis of Compound 1z
[0133]
[0134] Yellow solid; 1H NMR (400MHz, CDCl3): δ = 7.19 (dd, J1 = 15.2Hz, J2 = 11.6Hz, 1H, = CH), 7.12-7.06 (m, 1H, thiophene-H), 6.89 (d, J = 3.6Hz, 2H, 2x thiophene-H),6.34-6.21(m,2H,2x=CH),6.19-6.08(m,2H,2x=CH),5.89(s,1H,=CH),4.46(s,2H,CH2),2.02(t,J= 6.2Hz,2H,CH2),1.97(s,3H,CH3),1.70(s,3H,CH3),1.65-1.57(m,2H,CH2),1.49-1.43(m,2H,CH2),1.02(s,6H,2x CH3); 13 C NMR (100MHz, CDCl3): δ=171.6,156.1,141.6,140.8,137.7,137.1,133.1,132.8,130.2,129.3,126.7,125.2,123.5,117.8,39.6,3 4.2,33.1,28.9,27.7,21.7,19.2,12.9; IR(neat):v=3039,2955,2823,1674,1561,1437,1411,1262,1240,1198,1156,1075,1027cm -1 MS (70eV, EI) m / z (%): 382 (M + ,11.2),207(100); HRMS(EI)calcd m / z for C 24 H 30 O2S[M + ]: 382.1961, found 382.1955; HPLC purity: 96.1%.
[0135] Example 27: Synthesis of compound 1ab
[0136]
[0137] Yellow solid; 1H NMR (400MHz, CDCl3): δ = 11.76 (br, 1H, COOH), 7.04 (dd, J1 = 15.0Hz, J2 = 11.4Hz, 1H, = CH), 6 .37-6.25(m,2H,2x=CH),6.20-6.10(m,2H,2x=CH),5.80(s,1H,=CH),2.06-1.98(m,5H,CH2 and CH3),1.72(s,3H,CH3),1.66-1.58(m,2H,CH2),1.51-1.44(m,2H,CH2),1.03(s,6H,2x CH3); 13 C NMR (100MHz, CDCl3): δ=172.6,155.2,140.2,137.7,137.2,134.9,131.8,130.2,12 9.4,129.0,117.8,39.6,34.2,33.1,28.9,21.7,19.2,13.3(sept,J=19.2Hz),12.9.
[0138] To further illustrate the beneficial effects of the present invention, the following embodiments are provided.
[0139] Example 28: Western blot detection of the effect of the compound prepared in the present invention on LDLR protein expression in HepG2 cells.
[0140] Experimental procedure:
[0141] Cells were seeded at 100,000 cells per well in 12-well plates and cultured for 24 hours. The cells were washed twice with PBS the next day, then incubated overnight in serum-free RPMI 1640 medium containing 0.3% BSA. The compound of this invention and DMSO control were then added, and the cells were incubated for 24 hours. Cell lysis was then performed by adding 100 μL of SDS lysis buffer (62.5 mM Tris, pH 6.8, 1% SDS) to each well. Protein concentration was determined using a NanoDrop spectrophotometer. An equal volume of protein was loaded onto an SDS-PAGE gel and then transferred to a nitrocellulose membrane. The membrane was blocked in 5% skim milk, and then incubated overnight at 4°C with primary antibody. The membrane was then washed and incubated for 1 hour at room temperature with HRP-labeled secondary antibody. Developing was performed using an enhanced chemiluminescence (ECL) kit, and images were captured using a ChemiDoc Touch imaging system. The acquired images were analyzed using ImageJ software.
[0142] The relative LDLR protein level was calculated as the ratio of LDLR protein expression in the compound-treated group to LDLR protein expression in the DMSO control group, where the LDLR protein expression level in the control group was 1.0.
[0143] Experimental results:
[0144] Table 1 below shows the bioactivity results of the compounds obtained in the embodiments of the present invention, with the compound concentration being 25 μM:
[0145] Table 1
[0146]
[0147]
[0148] Among them, berberine is a compound reported in the literature that can increase LDLR protein levels (Nat. Med. 2004, 10, 1344–1351.).
[0149] The compounds listed in Table 1 can all increase the LDLR protein level in HepG2 cells. Most of the compounds have an effect on increasing the LDLR protein level comparable to berberine. Therefore, the compounds of the present invention can be used to treat diseases caused by cellular function abnormalities related to LDLR levels, especially cardiovascular diseases caused by lipid metabolism disorders.
[0150] Example 29: Western blot detection of the effect of compound 1t prepared in this embodiment on PCSK9 protein expression in HepG2 cells.
[0151] The experimental procedure is the same as that in Example 28 of this invention.
[0152] Experimental results:
[0153] The result is as follows Figure 1 As shown in the figure, the 1t compound significantly inhibited PCSK9 protein expression in a concentration-dependent manner. The inhibitory effect of 1t on PCSK9 protein levels was comparable to that of berberine, indicating that 1t has the potential to regulate PCSK9 expression and improve cellular dysfunction caused by abnormal PCSK9 expression, particularly in diseases related to lipid metabolism disorders. 1t holds promise as a candidate drug for the treatment of cardiovascular diseases, especially in pathological states involving high PCSK9 levels.
[0154] Example 30: The regulatory effect of compounds 1s and 1t prepared in this embodiment on LDL-C uptake in HepG2 cells.
[0155] Experimental procedure: HepG2 cells were stored at a density of 2 × 10⁶ cells per well. 5HepG2 cells were seeded at a density of [number] cells per well in black 96-well plates and cultured overnight. The medium was then removed and replaced with serum-free RPMI 1640 medium containing 0.3% bovine serum albumin (BSA), and cultured for another 24 hours. The cells were then treated with a compound for 24 hours, after which the cell culture medium was replaced with serum-free RPMI 1640 medium containing 0.3% BSA and 20 μg / mL DiI-LDL, and co-incubated with DiI-LDL for 4 hours. After incubation, HepG2 cells were washed three times with PBS containing 0.4% BSA, followed by two more washes with PBS. For quantitative fluorescence detection, 500 μL of isopropanol was added to each well, and the cells were incubated at room temperature in the dark for 20 minutes with continuous shaking. Fluorescence intensity was measured using a microplate reader at an excitation wavelength of 514 nm and an emission wavelength of 565 nm.
[0156] Experimental results:
[0157] The result is as follows Figure 2 As shown, compounds 1S and 1T of this invention significantly enhance LDL uptake in HepG2 cells, with effects comparable to those of traditional lipid-lowering drugs berberine and rosuvastatin. This indicates that compounds 1S and 1T of this invention have the ability to regulate cellular LDL-C uptake, and can be used to improve hypercholesterolemia caused by elevated LDL-C, providing a new treatment option for patients resistant to or poorly treated with statins.
[0158] The compounds of this invention significantly upregulate the functional expression of LDLR while inhibiting the expression of PCSK9, thereby enhancing cellular uptake of LDL-C. These molecular and cellular experimental results demonstrate that the compounds of this invention have a significant effect on regulating lipid metabolism and reducing LDL-C levels. Therefore, the compounds of this invention have potential applications in the prevention or treatment of diseases related to lipid metabolism abnormalities and hypercholesterolemia (such as atherosclerosis, coronary artery disease, etc.).
[0159] Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used in this specification is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
[0160] As used in this invention, the terms "comprising" and "including" are open-ended expressions, meaning they include the contents specified in this invention but do not exclude other aspects.
[0161] As used in this invention, the term "and / or" includes any one or more of the related listed items and all combinations thereof.
[0162] The scope of protection of this invention is not limited to the above embodiments. Any variations and advantages that can be conceived by those skilled in the art without departing from the spirit and scope of this invention are included in this invention and are protected by the appended claims.
Claims
1. An isoprenic acid derivative or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, a solvate thereof, or a prodrug thereof, characterized in that, The structure of the isoprenic acid derivative is shown in formula (I): R 1 It can be methyl, phenyl, aryl, heterocyclic, hydrocarbon, hydrocarbon with functional groups, or deuterated hydrocarbon; R 2 It can be phenyl, aryl, heterocyclic, hydrocarbon, or hydrocarbon with a functional group; n can be 1, 2, 3 or 4.
2. A drug / drug composition, characterized in that, It comprises a therapeutically effective amount of one or more isoprenic acid derivatives as described in claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a solvate thereof, or a prodrug thereof as an active ingredient, and pharmaceutically acceptable excipients.
3. Use of the isoprenic acid derivative of claim 1 or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, a solvate thereof, or a prodrug thereof, or the drug / drug composition of claim 2, in the preparation of a medicament for treating and / or preventing and / or alleviating diseases associated with lipid metabolism disorders.
4. Use of the isoprenic acid derivative of claim 1 or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, or a solvate thereof or a prodrug thereof, or the drug / drug composition of claim 2, in the preparation of a drug for regulating and / or increasing low-density lipoprotein receptor (LDLR) levels.
5. Use of the isoprenic acid derivative of claim 1 or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, a solvate thereof, or a prodrug thereof, or the drug / drug composition of claim 2, in the preparation of a drug for regulating and / or inhibiting the level of the proprotein convertase subtilisin 9PCSK9.
6. Use of the isoprenic acid derivative of claim 1 or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, a solvate thereof, or a prodrug thereof, or the drug / drug composition of claim 2, in the preparation of a medicament for treating a disease or condition associated with abnormal LDLR levels.
7. Use of the isoprenic acid derivative of claim 1 or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, a solvate thereof, or a prodrug thereof, or the drug / drug composition of claim 2, in the preparation of a medicament for treating a disease or condition associated with abnormal PCSK9 levels.
8. The use according to claim 6 or 7, characterized in that, The diseases or conditions mentioned include those related to abnormal lipid metabolism, abnormal cholesterol levels and dyslipidemia, cancer and / or other conditions.
9. The use according to claim 3 or 8, characterized in that, The diseases associated with lipid metabolism abnormalities include cardiovascular diseases, metabolic diseases, and endocrine disorders; And / or, the abnormal cholesterol levels include fatty liver.
10. The use according to claim 9, characterized in that, The cardiovascular diseases mentioned include atherosclerosis, coronary heart disease, coronary artery disease, myocardial infarction, and stroke; And / or, the metabolic diseases include diabetes, obesity, metabolic syndrome, and insulin resistance. And / or, the endocrine disorders include hyperlipidemia and hypercholesterolemia.
